Nam Atiqur Rahman

9PUBLICATIONS
107CO-AUTHORS
Molecular targetsGene and molecular therapyMedical biotechnology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Flight dynamics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 12, 2026
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

|Sep 05, 2025
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Michael I Barbato, Amy K Barone, Stephanie L Aungst

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Jan 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.

Sonia Singh, Diana Bradford, Somak Chatterjee

|Sep 04, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

Michael H Brave, William F Maguire, Chana Weinstock

|Jul 29, 2024
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs.

Atiqur Rahman, Mirat Shah, Stacy S Shord

Pageof 2

Frequent Collaborators

7 joint publications

Richard Pazdur

6 joint publications

Paul G Kluetz

6 joint publications

Shenghui Tang

4 joint publications

Laleh Amiri-Kordestani